Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Sara M TolaneyNabihah TayobChau DangDenise A YardleySteven Jay IsakoffVicente ValeroMeredith FaggenTherese Marie MulveyRon BoseJiani HuDouglas WecksteinAntonio C WolffKatherine E Reeder-HayesHope S RugoBhuvaneswari RamaswamyDan ZuckermanLowell HartVijayakrishna K GadiMichael ConstantineKit ChengFrederick BriccettiBryan Paul SchneiderAudrey Merrill GarrettP Kelly MarcomKathy S AlbainPatricia DeFuscoNadine M TungBlair ArdmanRita NandaRachel C JankowitzMothaffar F RimawiVandana G AbramsonPaula R PohlmannCatherine H Van PoznakAndres Forero-TorresMinetta C LiuKathryn J RuddyYue ZhengShoshana M RosenbergRichard D GelberLorenzo TrippaWilliam BarryMichelle DeMeoHarold BursteinAnn H PartridgeEric P WinerIan E KropPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.